Risk of escalating EU-U.S. trade tensions remains with deadline ahead

Barclays analysts highlight significant uncertainty in ongoing US-EU trade negotiations as a tariff pause approaches expiration, noting internal EU divisions on negotiation strategy. Their base case predicts an average 15% US tariff on EU goods, with duties on pharmaceutical and semiconductor companies potentially rising to 25%. Barclays identifies an upside risk of lower effective tariffs via quotas, but a downside risk of reciprocal tariffs exceeding 10% if talks fail, underscoring continued trade tensions and potential market impacts.

Analysis

Uncertainty surrounding US-EU trade negotiations is elevated as a key tariff pause deadline approaches, with Barclays analysts highlighting a significant risk of escalating tensions. Internal divisions within the EU are a critical factor, as Germany and Italy reportedly favor a swift agreement while France advocates for a more assertive stance, complicating the bloc's negotiating position. Barclays' base case forecasts an average US tariff rate of 15% on EU goods, with a specific and acute impact on the pharmaceutical and semiconductor sectors, where duties could rise to 25%. While an upside risk exists for a lower effective tariff rate through quotas or sector-specific deals, the downside risk of failed talks leading to reciprocal tariffs above 10% remains substantial. The situation reflects a moderately negative outlook, underscoring the potential for market volatility driven by geopolitical trade policy.

Key Decisions for Investors

• Investors should immediately review and potentially hedge exposure to European pharmaceutical and semiconductor companies with significant U.S. sales, as these sectors face a specific risk of 25% tariffs in Barclays' base case scenario.
• Monitor diplomatic communications closely, particularly from Germany and France, as their divergent stances are a key indicator of the EU's negotiating resolve and the likelihood of a unified response versus a concessionary deal.
• Given the high uncertainty and potential for talks to fail, consider reducing exposure to European export-oriented equities until there is more clarity, as the downside risk of tariffs exceeding 10% could negatively impact corporate earnings and market sentiment.